Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Apotex Acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
Details : Acquiring the US rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil) indicated to improve wakefulness in adult patients marks a strategic milestone for Apotex.
Product Name : Provigil
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition
Neuraxpharm Acquires Provigil®, Nuvigil® to Expand Branded Business
Details : Neuraxpharm has acquired these products Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of EDS in adults with narcolepsy.
Product Name : Provigil
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 07, 2025
Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Modafinil
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Chemipharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2023
Lead Product(s) : Modafinil
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Chemipharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Modafinil
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access of Vigil in Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 15, 2019
Lead Product(s) : Modafinil
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Modafinil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Ontario Ministry of Health and Long Term Care | The Canadian Biomarker Integration Network in Depression
Deal Size : Inapplicable
Deal Type : Inapplicable
Modafinil's Effects on Cognition in Remitted MDD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2018
Lead Product(s) : Modafinil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Ontario Ministry of Health and Long Term Care | The Canadian Biomarker Integration Network in Depression
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 12, 2018
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 08, 2017
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 01, 2016
Vigilâ„¢ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 24, 2015
Pilot Study of Vigilâ„¢ + Pembrolizumab for Advanced Melanoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 14, 2015
Reset All
